Clinical trial
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants…
NCT00265122 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00265122 |
|---|---|
| Title | A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease |
| Official title | A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC, Placebo IV |
| Enrollment | 131 |
| Start date | Apr 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Dec 14, 2005 |
| Last update posted | Feb 13, 2014 |
| Countries | Belgium, Canada, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: